anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
961,813. Densifying powdered materials. AMERICAN CYANAMID CO. March 18, 1963, No. 10658/63. Heading B5A. In an apparatus for densifying powdered materials aerated powdered material is fed to a hopper 16, wherein a sealing head of 22 inches is maintained, and thence along a horizontal side feed chamber 17 to between the top and second flights of a feed screw 20 in a vertical conical chamber 19, the apex and discharge of which is at the bottom, the upper third of the interior surface of the chamber 19 being adapted so that the aerated powdered material does not freely spin against said interior surface, e.g. by having a roughened surface, Fig. 3 (not shown), or having the inner surface as a filter plate 53 connected to a vacuum manifold 52, Fig. 4 (not shown), and the lower two-thirds of the interior surface of the chamber being very highly polished. A vacuum manifold 25 is connected across the wide mouth of the chamber 19 having in it a filter plate 26 so that air may be removed from the powdered material. The material is fed compacted and deaerated to a pair of pressure densifying rolls 29 which are corrugated, the longitudinal depressed portions of one corresponding to the undepressed portions of the other, and enclosed in an air-tight jacket 31 having an air nozzle 32 feeding in conditioned air which aids the movement of the stream of material from the rolls 29 to a granulator 34. When the material has been densified it is blown into a hopper 36 and thence through a filter mechanism 40, 41 which removes fines and returns them to the hopper 16.
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the primary cause of dementia. It brings about a huge burden for patients, families and society as a whole. There is currently no curative treatment available, but the existence of a long preclinical period, during which biomarker changes are observed, and the identification of modifiable risk factors suggest that AD may be preventable. Data is currently lacking, however, on the trajectories and predictive value of blood-based biomarkers (which are more acceptable and less costly to measure than traditional imaging and Cerebrospinal fluid biomarkers biomarkers). Furthermore, although there has been much research into modifiable AD risk factors, they have often not been studied simultaneously in the same cohort, and there has been relatively little research into newly identified risk factors, such as hearing impairment. First-degree relatives of AD patients would seem an ideal population to study such factors, since they are at increased risk of dementia and cognitive decline, and may be more motivated to participate in dementia research studies than other individuals. Finally, although caregiver burden and quality of life have been previously studied, further data is required on their longitudinal trajectories, particularly taking into account the disease course of the patients they care for. Caregivers' needs and coping and caregiving strategies also need to be better understood. In the pilot phase of the ALFA3 study, 150 familial clusters (each comprised of a patient with Alzheimer's disease, a family caregiver and at least one first-degree relative of the patient) will be recruited and followed-up for 2 years in expert memory centers and via online questionnaires. This pilot phase will be used to study the feasibility of conducting a larger-scale study.
FIELD: medicine; neurosurgery; surgical treatment of ischemic disease of brain. SUBSTANCE: first surgeon must provide surgical access to operation field, and must mobilize carotid artery of vertebral artery. Thereupon, o prevent thrombogenesis, patient's vascular bed must be subjected to heparinizing treatment according to generally accepted procedures for vascular surgery by intravenously administering 5 ths.units heparin. It is generally assumed that heparin starts acting, on average, upon passage of 5 min. after injection. Next, upon passage of 3 min., also intravenously, 1 mg delargin diluted in 2-3 ml of physiological solution is administered. Upon expiration of 2 min, i. e. time required for neuropeptide to start acting, patient's blood flow in artery being operated is interrupted by applying artery forceps or special spring-urged clamps onto artery's proximal and distal segments. Finally, surgeon must proceed to required reconstructive surgical operation for eliminating main pathogenic factor causing ischemic disease of brain. EFFECT: enhanced treatment efficiency.
Epithelioid hemangioendothelioma is a rare vascular tumor originating from vascular endothelial or pre-endothelial cells. We present the case of a 4-month-old male with a rapidly enlarging left zygomatico-orbital tumor causing mass effect on the eye globe. Examination revealed a large, nontender, solid lesion. CT angiography showed no major feeder or intralesional vessels. Complete surgical excision was performed, which was complicated by life-threatening intraoperative bleeding and successfully controlled with electrocautery. Microscopically, tumor cells exhibited varying morphologies. Immunohistochemistry confirmed the diagnosis of epithelioid hemangioendothelioma (positive for CD31 and CD34, negative for CK AE1/AE3). We also highlight 2 similar case reports with life-threatening bleeding complications. Surgeons should be aware of this condition and optimize surgical preparation, including blood products, to manage potential bleeding complications.
Neuroinflammation plays crucial role in the development and progression of depression. Large conductance calcium- and voltage-dependent potassium (BK) channels mediate the activation of microglia. Herein, we investigated whether BK channels could serve as a target for the treatment of inflammation-associated depression. Lipopolysaccharide (LPS, 0.83 mg/kg) was injected intraperitoneally (i.p.) to induce neuroinflammation and depressive-like behavior in 6-8 week ICR mice. Adeno-associated virus (AAV) constructs (AAV9-Iba1p-BK shRNA-EGFP (BK shRNA-AAV) or AAV9-Iba1p-NC shRNA-EGFP (NC shRNA-AAV)) were unilaterally injected intracerebroventricularly to selectively knock down BK channels in microglia. The tail suspension test (TST) and forced-swim test (FST) were used to evaluate depressive-like behavior in mice 24 h after LPS challenge. The morphology of microglia, expression of BK channels, levels of cytokines, and expression and activity of indoleamine 2,3-dioxygenase (IDO) were measured by immunohistochemistry, western blot, quantitative real time PCR, and enzyme-linked immunosorbent assay (ELISA), respectively. Either paxilline (i.p.), a specific BK channel blocker, or BK shRNA-AAV effectively inhibited the activation of microglia, reduced the production of IL-1β in the hippocampus and suppressed the expression and activity of IDO in the hippocampus and prefrontal cortex, resulting in the amelioration of depressive-like behavior in mice. These data suggest for the first time that BK channels are involved in LPS-induced depressive-like behaviors. Thus, microglia BK channels may be a potential drug target for the depression treatment.
Objectives: To evaluate the cognitive performance of obese patients with MCI and the effect of weight loss induced by caloric restriction on cognition, conversion to dementia, to assess weight loss, changes in inflammatory and metabolic parameters, change in physical capacity, performance in neuropsychological tests and correlate with effects of the intervention. Methods: The patients will be randomized to two groups that will be followed for 12 months. The control group will receive conventional medical care. The intervention group will receive nutritional counseling individually and in groups, aiming to promote weight loss (10% of body weight) through caloric restriction, and medical monitoring. Everyone will be advised to physical activity. Before and after 12 months patients will be evaluated for anthropometry, body composition, physical performance, control of comorbidities, laboratory tests (glucose, insulin, lipid profile, leptin, adiponectin, interleukin 6, tumor necrosis factor alpha, CRP), Genotyping apolipoprotein E, neuropsychological battery, questionnaires about activities of daily living, physical activity and diet.
PURPOSE: The aim of this study is to evaluate the efficacy of heated humidified high flow nasal cannula (HFNC) therapy as a conservative treatment option for newborns suffering from nasal stenosis, a condition that often leads to respiratory distress and feeding difficulties. Given the increasing utilization of HFNC in various upper and lower respiratory tract indications, characterized by its flow-based mechanism and minimal mucosal damage, we seek to investigate its potential benefits in this specific patient population.
METHODS: A retrospective chart review of newborns with congenital nasal stenosis treated with HFNC for respiratory distress or feeding difficulties in a pediatric tertiary center between 2014 and 2022. Data were collected for demographic characteristics, clinical presentation and ventilatory requirements, pre and post HFNC application.
RESULTS: Six infants with nasal stenosis were included in the study cohort. Five were diagnosed with congenital pyriform aperture stenosis, three of whom had additional midnasal stenosis. One patient had nasal synechiae. Two patients had failed surgical treatment and all patients failed conservative treatment prior to HFNC treatment. Following HFNC use, improvement was noted in oxygen saturations, heart and respiratory rates, meal volumes and weight. None of the patients required any additional sinonasal surgical treatment. No complications were observed.
CONCLUSIONS: In this case series, we present the first documented use of HFNC treatment for nasal stenosis, showing favorable results. Further studies with a larger cohort, wider range of conditions and extended follow-up periods are needed to establish the risks and benefits of HFNC for neonatal nasal stenosis.
Sleep problems include insomnia, circadian rhythm disorders, hypersomnia, and inadequate sleep hygiene. Patients suffering from mental illness are more likely to suffer from sleep problems than the general population. Sleep problems can aggravate the underlying disorder, cause relapse and suicidal ideation. Sleep problems often persist after the mental disorder is successfully treated. Sleep medication is often used but not recommended for long term use. Non-pharmacological treatment of sleep problems is in demand by patients, but treatment options are few. The present intervention is based on a transdiagnostic manual combining Cognitive Behavioral Therapy for Insomnia with chronotherapy, but more research on the efficacy is warranted.

The aim of this study is to investigate whether the intervention reduces the severity of the sleep problem, increases sleep quality, leads to increased sleep efficiency, reduces sleep latency and awakenings, provides better quality of life, increases personal recovery, provides greater readiness to take on a job or reduces consumption of sleep medication.
PURPOSE: A composition containing a Schizonepeta tenuifolia var. japonica extract for promoting growth or preventing and treating osteoporosis is provided to excellently increase osteoporosis and to be used as a pharmaceutical composition for promoting growth or preventing and treating osteoporosis. CONSTITUTION: A pharmaceutical composition for promoting growth and preventing and treating osteoporosis contains 0.1-50 wt% of a Schizonepeta tenuifolia var. japonica extract as an active ingredient. The extract is a crude extract, a polar solvent-soluble extract, or a non-polar solvent-soluble extract of Schizonepeta tenuifolia var. japonica. The crude extract is prepared by extracting with water including purified water, C1-C4 alcohol, or a mixture thereof. The polar solvent-soluble extract is prepared using water, methanol, ethanol, butanol, or a mixture thereof. The non-polar solvent-soluble extract is prepared using hexane, chloroform, or ethyl acetate.
The proposed study will be a single-center, prospective, crossover-controlled study of the two anesthetic techniques (propofol and sevoflurane). The investigators plan to enroll 80 patients who receive general anesthesia at Cincinnati Children's Hospital Medical Center Department of Radiology for ABR testing. A sample size recalculation will be performed during the study to determine the exact number of subjects necessary for sufficient power. As per standard anesthesia practice for this test in radiology department, all subjects will serve as their own control, receiving both anesthetic techniques within the same ABR testing session. The audiologist will employ broadband click stimulus testing after induction with Sevoflurane, after which the patient will be switched over to a propofol infusion and the sevoflurane stopped. After the completion of the remainder of the ABR (tone-burst testing), the audiologist will repeat the broadband click testing (now while under propofol anesthesia), and the results will be recorded. At this point, results will be de-identified, with the exception of which ear was tested and the intensity level, and these results will be reviewed by a panel of 5 audiologists. These audiologists will be blinded to the anesthetic technique and patient information. They will provide a judgment at each intensity level, for each ear whether or not a response is present (in a Yes/No format). A study coordinator blinded to the anesthetic technique will record the outcome data. The anesthesia providers and nursing team will not be blinded.
The invention discloses a burn treatment medicine and a preparation method thereof. The burn treatment medicine comprises 150g of American ginseng, 100g of Ganoderma Lucidum Karst, 100g of lily, 100g of fig pollen, 50g of Chinese angelica, 50g of safflower, 50g of Rhizoma Polygoni Cuspidati, 100g of Polygonatum odoratum, 200g of Chinese fevervine herb, 50g of Amur Corktree Bark, 50g of Cynoglossum lanceolatum Forsk. and 50g of Diverse Wormwood Herb. The method comprises the following steps: taking 2.5kg of sesame oil and 2.5kg of lard, adding traditional Chinese medicines according to the boiling point temperature, and extracting pure medicinal oil at a high temperature; blending with beeswax as a matrix to form an ointment; carrying out low temperature treatment to remove fire toxins; and grinding. The burn treatment medicine is a pure traditional Chinese medicinal component, is locally used to improve the blood circulation of damaged tissues and increase the nerve and nutrition supply to the damaged skins, fully shows medicinal effects, and can be used to realize automatic liquefaction, automatic drainage, automatic restoration and natural annular healing. The burn treatment medicine makes wounds form a barrier to prevent bacteria from intervening and reaching wounds in order to realize no infection.
No breakfast will be provided until the lunch time at \~12:30. Blood samples will be taken at fasting state and postprandially at different intervals after breakfast and lunch for the measurement of glucose and insulin concentrations.
In every cluster designated as a control group, patients aged 65 or older will be selected according to the inclusion criteria. The difference here is that patients will be given the standard opportunistic screening instead: pulse palpation and a 12-lead ECG when an irregular rhythm is found. This is current best practice.
Methods of treating or preventing disorders using compounds that regulate TRPV 4 pathway are described. Methods and cells that can be used to evaluate compounds, such as TRPV 4 antagonists, for treatment or prevention disorders are also provided. In some embodiments, the TRPV 4 antagonist is selected, at least in part, on the basis that it is a TRPV 4 antagonist. In some embodiments, the TRPV 4 antagonist does not inhibit one, two, or all of TRPV1, TRPV2, and TRPV3. In some embodiments, the TRPV4 antagonist inhibits one, two, or all of TRPV1, TRPV2, and TRPV3. In some embodiments, the TRPV 4 antagonist is selected from the group consisting of rimonabant, AMG-251, AMG9810, GSK205, and BCTC.
PURPOSE:The titled protecting material, containing an alpha-cyanoacrylate and a silica type filler, capable of being pasted, having retained transparency, and easily operable. CONSTITUTION:A protecting material for the dental pulp, obtained by incorporating an alpha-cyanoacrylate of the formula (R is 1-16C alkyl, phenyl or cyclohexyl) with a silica type filler. The use of fine particulate silicic anhydride as the filler provides a stable pasty material. The curing rate of the composition is somewhat lower than the simple alpha-cyanoacrylate, and the suitable application time for the protecting operation of the dental pulp makes the operation easy. The protecting effect is not inferior to that of the simple alpha-cyanoacrylate. The resultant material will scarcely cause a lesion in the dental pulp, and the blocking effect on the irritation to the dental pulp of a reparative material.
Patients receive cetuximab 400mg/m\^2 IV over 2 hours on the first day of treatment, then 250 mg/m\^2 IV over 1 hour weekly thereafter. Patients also receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
BACKGROUND: Pneumomediastinum signifies the accumulation of air within the mediastinum. This condition can develop sponta-neously or as a secondary condition due to trauma or iatrogenic causes. Although rare, it is part of a wide differential diagnosis scale due to its most common presenting symptoms: chest pain and shortness of breath.
METHODS: Our study is a retrospective, observational, and cohort investigation. It included patients who presented to the emer-gency department and were diagnosed with pneumomediastinum through computed tomography. The study evaluated patients' so-ciodemographic features, methods of presentation, chest tube insertion, other surgical procedures, outcomes, and patient dispositions. The primary outcome of the study focused on the results of traumatic and spontaneous pneumomediastinum: hospital admission, the necessity for thoracostomy tube insertion, requirement for surgical procedures, and mortality. The secondary aim was to determine the relationship between other clinical features and laboratory parameters and their impact on the outcomes.
RESULTS: The study comprised 67 cases. The average age of the cases was 44.89±2.41 years. Of the cases, 67.2% (n=45) were male. In terms of development, 40.3% (n=27) of cases were classified as spontaneous, and 59.7% (n=40) were post-trauma pneumomediasti-num diagnoses. Among symptoms, 50.7% (n=34) of patients experienced dyspnea, and 49.3% (n=33) presented with chest pain, while symptoms like cough, fever, nausea, vomiting, and swallowing difficulty were reported in varying proportions. Among the patients, 9.0% (n=6) had lung disease, 29.9% (n=20) had comorbidities, 3.0% (n=2) had a history of substance use, 14.9% (n=10) underwent thoracostomy tube insertion, and 20.9% (n=14) required surgical procedures. While 35.8% (n=24) of the patients were admitted to the intensive care unit, 13.4% (n=9) died. The mean total hospital stay was calculated as 8.68±1.12 days. No statistically significant relationship was found between the development of pneumomediastinum and hospital admission (p=0.507).
CONCLUSION: Upon examining the causes of pneumomediastinum cases, it was observed that patients with a history of trauma required thoracostomy tube insertion and surgical intervention more frequently. However, when classified as spontaneous or trau-matic, both groups exhibited similar clinical courses and outcomes. Both groups demonstrated favorable clinical outcomes.
Osteoporosis is an uncommon disease in children and early adolescents. Patients have a low bone mineral density, develop fractures with minimal or no trauma, and frequently have a negative family history. The disease results from either diminished bone formation or increased bone removal (resorption). No specific drug therapy has been recommended for juvenile osteoporosis. Alendronate (Fosamax) is effective in inhibiting bone resorption, increasing BMD and reducing fractures in adults with postmenopausal osteoporosis, but have not become established therapies in children. In the present study, we plan to evaluate the safety and efficacy of Alendronate in 20 patients with juvenile osteoporosis in a two-year period. This is a randomized, double-blind, placebo-controlled protocol. In the year-1, 10 patients will be assigned to receive Alendronate and 10 patients placebo. In the year-2, patients will be crossed over to the second arm of the study. Those who received Alendronate in the year-1, will receive placebo in the second year and vice verse. The patients will have 5 visits, the initial screening visit followed by 4 post therapy visits in a six-month interval. Measurements include DXA bone density scan of spine and hip, urinalysis and blood work.
URGO AWC_008 or URGO AWC_022 dressing. These 2 dressings are similar and only the adhesive constitutes a difference. The choice of study dressing will be left to the discretion of the investigator during the treatment of the patient, depending on the nature of the wound and the condition of the peri-wound skin.
BACKGROUND: Little is known about the effect of surgical approach on return to braking after total hip arthroplasty (THA), and few studies have investigated braking after THA with modern surgical techniques and rehabilitation protocols.
METHODS: In a prospective comparative design, we enrolled 65 patients who received right-sided primary THA at our institution from April 2018 through March 2020, 34 with a direct anterior approach (DAA) and 31 with a posterior approach (PA). Braking tests measuring brake reaction time (BRT) and brake pedal depression (BPD) were administered to patients preoperatively and at 1, 2, and 4 weeks postoperatively using a realistic driving simulator. BRT and BPD were compared between groups and preoperatively versus postoperatively using mixed-effects models.
RESULTS: Preoperative BRT averaged 638 msec in the DAA group and 604 msec in the PA group (P = 0.31). At 1 week postoperatively, the DAA group had significantly prolonged BRT compared with preoperatively (694 msec, P = 0.02). No significant difference was observed in the PA group (633 msec, P = 0.31). Both groups had returned to baseline by 2 weeks, and both had significantly faster BRT at 4 weeks compared with preoperatively (583 msec for DAA, P = 0.01; 537 msec for PA, P < 0.001). BPD was similar between groups, and there were no significant differences between preoperative and postoperative BPD at any time point.
CONCLUSIONS: With modern surgical techniques, BRT after right-sided THA returns to baseline levels approximately 2 weeks after surgery. There seems to be a quicker return to preoperative BRT observed in patients with a PA.
PURPOSE:To obtain a physiologically active peptide amide useful as pharmaceuticals, etc., by treating a specific precursor in an aqueous medium with a C-terminal amidation enzyme originated from mammal. CONSTITUTION:A fish calcitonin derivative (precursor) having amino acid sequence of formula (X is Asn or Asp; Y is Thr or Val; Z is Sr or Ala) is mixed with a C-terminal amidation enzyme extracted from swine pituitary gland, etc. The obtained aqueous medium is added with 20-100muM of copper ion, 100-500muM of ascorbic acid, 50-200mug/ml of catalase and 50-1,000muM of serine protease inhibitor (e.g. phenylmethylsufonyl fluoride) and/or thiol protease inhibitor (e.g. N-ethylmaleimide) and made to react at 20-42 deg.C and 6-9pH. The reaction medium is purified and the objective physiologically active peptide amide is collected from the medium.